Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 21 | 2025 | 186 | 10.170 |
Why?
|
| Thrombotic Microangiopathies | 12 | 2024 | 54 | 6.270 |
Why?
|
| Anticoagulants | 15 | 2024 | 609 | 4.070 |
Why?
|
| Neoplasms | 19 | 2025 | 2955 | 3.760 |
Why?
|
| Venous Thrombosis | 8 | 2024 | 172 | 3.650 |
Why?
|
| Pulmonary Embolism | 6 | 2024 | 189 | 2.820 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2024 | 1197 | 2.710 |
Why?
|
| Thrombosis | 7 | 2025 | 524 | 2.690 |
Why?
|
| Plasma Exchange | 7 | 2025 | 88 | 2.130 |
Why?
|
| ADAMTS13 Protein | 7 | 2025 | 66 | 1.800 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 6 | 2025 | 56 | 1.600 |
Why?
|
| Thromboembolism | 3 | 2025 | 93 | 1.490 |
Why?
|
| Urate Oxidase | 2 | 2020 | 17 | 1.260 |
Why?
|
| Hemorrhage | 8 | 2025 | 519 | 1.250 |
Why?
|
| Safety-net Providers | 3 | 2025 | 70 | 1.230 |
Why?
|
| Factor Xa Inhibitors | 3 | 2024 | 66 | 1.220 |
Why?
|
| Hyperuricemia | 2 | 2020 | 41 | 1.210 |
Why?
|
| Multiple Myeloma | 3 | 2023 | 204 | 1.200 |
Why?
|
| Risk Assessment | 15 | 2025 | 3736 | 1.190 |
Why?
|
| Risk Factors | 24 | 2025 | 10941 | 1.190 |
Why?
|
| Graft vs Host Disease | 4 | 2023 | 627 | 1.150 |
Why?
|
| Incidence | 10 | 2025 | 3378 | 0.980 |
Why?
|
| Retrospective Studies | 27 | 2025 | 17391 | 0.950 |
Why?
|
| Single-Payer System | 1 | 2024 | 2 | 0.880 |
Why?
|
| Aged | 28 | 2025 | 21415 | 0.880 |
Why?
|
| Humans | 67 | 2025 | 131985 | 0.860 |
Why?
|
| Lymphoma | 2 | 2025 | 331 | 0.860 |
Why?
|
| Adult | 30 | 2025 | 31547 | 0.860 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 39 | 0.850 |
Why?
|
| Splanchnic Circulation | 1 | 2024 | 51 | 0.830 |
Why?
|
| Middle Aged | 29 | 2025 | 28976 | 0.800 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2020 | 11 | 0.780 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2019 | 26 | 0.710 |
Why?
|
| Health Status Disparities | 1 | 2024 | 253 | 0.700 |
Why?
|
| Male | 38 | 2025 | 64910 | 0.670 |
Why?
|
| Female | 38 | 2025 | 70623 | 0.650 |
Why?
|
| Vitamin K | 2 | 2019 | 38 | 0.650 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 576 | 0.650 |
Why?
|
| Blood Coagulation | 2 | 2024 | 130 | 0.640 |
Why?
|
| Rivaroxaban | 2 | 2019 | 57 | 0.630 |
Why?
|
| Thalidomide | 1 | 2019 | 40 | 0.630 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 698 | 0.620 |
Why?
|
| Dalteparin | 1 | 2019 | 5 | 0.620 |
Why?
|
| Hospital Mortality | 3 | 2021 | 1057 | 0.610 |
Why?
|
| Allopurinol | 1 | 2020 | 75 | 0.600 |
Why?
|
| Thiazoles | 1 | 2019 | 100 | 0.590 |
Why?
|
| Gout Suppressants | 1 | 2019 | 72 | 0.570 |
Why?
|
| Cohort Studies | 11 | 2023 | 5166 | 0.550 |
Why?
|
| Pyridines | 1 | 2019 | 249 | 0.550 |
Why?
|
| Administration, Oral | 5 | 2020 | 698 | 0.530 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 256 | 0.530 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 1657 | 0.520 |
Why?
|
| Prognosis | 8 | 2025 | 5008 | 0.520 |
Why?
|
| Transplantation, Homologous | 4 | 2022 | 652 | 0.470 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 7100 | 0.450 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 130 | 0.450 |
Why?
|
| Biomarkers | 5 | 2024 | 3406 | 0.440 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 310 | 0.440 |
Why?
|
| United States | 11 | 2025 | 11653 | 0.430 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1825 | 0.400 |
Why?
|
| Registries | 1 | 2019 | 1579 | 0.380 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 845 | 0.380 |
Why?
|
| Atrial Fibrillation | 2 | 2017 | 758 | 0.370 |
Why?
|
| Time Factors | 3 | 2025 | 6443 | 0.320 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 141 | 0.300 |
Why?
|
| Uric Acid | 2 | 2020 | 110 | 0.300 |
Why?
|
| Secondary Prevention | 2 | 2021 | 223 | 0.290 |
Why?
|
| Hemostasis | 2 | 2025 | 73 | 0.280 |
Why?
|
| Immunologic Factors | 2 | 2019 | 183 | 0.280 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 1458 | 0.270 |
Why?
|
| Treatment Outcome | 10 | 2025 | 13019 | 0.270 |
Why?
|
| Warfarin | 2 | 2019 | 129 | 0.260 |
Why?
|
| Propensity Score | 2 | 2020 | 257 | 0.260 |
Why?
|
| Prospective Studies | 4 | 2024 | 6569 | 0.250 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 295 | 0.250 |
Why?
|
| Inpatients | 3 | 2025 | 550 | 0.240 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 2317 | 0.240 |
Why?
|
| Mutation | 3 | 2025 | 6227 | 0.240 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 3089 | 0.240 |
Why?
|
| Anemia, Hemolytic | 1 | 2025 | 32 | 0.230 |
Why?
|
| von Willebrand Factor | 2 | 2025 | 192 | 0.230 |
Why?
|
| Liquid Biopsy | 1 | 2024 | 16 | 0.220 |
Why?
|
| Dioxygenases | 1 | 2025 | 68 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2025 | 2849 | 0.220 |
Why?
|
| Texas | 2 | 2024 | 3628 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 3351 | 0.210 |
Why?
|
| Age Factors | 3 | 2025 | 2913 | 0.210 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 156 | 0.200 |
Why?
|
| SEER Program | 1 | 2024 | 220 | 0.200 |
Why?
|
| Natural Language Processing | 1 | 2024 | 73 | 0.200 |
Why?
|
| Complement System Proteins | 1 | 2023 | 59 | 0.200 |
Why?
|
| Rituximab | 2 | 2025 | 168 | 0.190 |
Why?
|
| Heparin | 1 | 2024 | 212 | 0.190 |
Why?
|
| Central Venous Catheters | 1 | 2023 | 48 | 0.190 |
Why?
|
| Survival Rate | 4 | 2025 | 2192 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2025 | 301 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 1132 | 0.190 |
Why?
|
| Time-to-Treatment | 2 | 2021 | 210 | 0.190 |
Why?
|
| Germ Cells | 1 | 2023 | 204 | 0.180 |
Why?
|
| Hospitalization | 2 | 2024 | 1898 | 0.180 |
Why?
|
| Medically Uninsured | 1 | 2022 | 78 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 345 | 0.180 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 38 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 298 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 613 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2025 | 363 | 0.170 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2021 | 31 | 0.170 |
Why?
|
| Child | 5 | 2025 | 25762 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 368 | 0.170 |
Why?
|
| Electronics, Medical | 1 | 2020 | 9 | 0.170 |
Why?
|
| Veterans | 2 | 2023 | 1761 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 147 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1161 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2025 | 812 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 256 | 0.160 |
Why?
|
| Recurrence | 2 | 2021 | 1468 | 0.160 |
Why?
|
| Consensus | 1 | 2023 | 649 | 0.160 |
Why?
|
| Twins | 1 | 2020 | 72 | 0.160 |
Why?
|
| Electronic Health Records | 2 | 2024 | 800 | 0.160 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 72 | 0.160 |
Why?
|
| Unrelated Donors | 1 | 2020 | 70 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 161 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 83 | 0.160 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 38 | 0.160 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 185 | 0.150 |
Why?
|
| Survivors | 1 | 2021 | 354 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 131 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 125 | 0.150 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2019 | 54 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2019 | 183 | 0.140 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 158 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 1246 | 0.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2019 | 162 | 0.130 |
Why?
|
| Disease Progression | 1 | 2024 | 2222 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 237 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2019 | 362 | 0.130 |
Why?
|
| Prevalence | 1 | 2024 | 2658 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3410 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2025 | 1977 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2021 | 384 | 0.130 |
Why?
|
| Patient Safety | 1 | 2021 | 440 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2020 | 1254 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1396 | 0.120 |
Why?
|
| Disease Management | 1 | 2020 | 563 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 540 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 540 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 3011 | 0.120 |
Why?
|
| Medicare | 1 | 2019 | 447 | 0.120 |
Why?
|
| Aminocaproic Acid | 1 | 2015 | 4 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1378 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1535 | 0.120 |
Why?
|
| Heart-Assist Devices | 1 | 2024 | 1078 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2015 | 84 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 672 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2019 | 744 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2019 | 1229 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1183 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2025 | 311 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 233 | 0.100 |
Why?
|
| Body Weight | 1 | 2017 | 994 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 898 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 672 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1743 | 0.080 |
Why?
|
| Adolescent | 3 | 2025 | 20535 | 0.080 |
Why?
|
| Infant | 2 | 2023 | 13047 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8542 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2023 | 14732 | 0.080 |
Why?
|
| Sex Factors | 2 | 2025 | 1353 | 0.070 |
Why?
|
| Young Adult | 4 | 2025 | 9952 | 0.070 |
Why?
|
| HIV Infections | 1 | 2020 | 2035 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 958 | 0.070 |
Why?
|
| Single-Domain Antibodies | 1 | 2025 | 9 | 0.060 |
Why?
|
| Acute Disease | 2 | 2020 | 1160 | 0.060 |
Why?
|
| Platelet Count | 1 | 2025 | 139 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2025 | 80 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2025 | 132 | 0.060 |
Why?
|
| Partial Thromboplastin Time | 1 | 2024 | 47 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 155 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2025 | 617 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 174 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2025 | 386 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 333 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2025 | 456 | 0.050 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2021 | 20 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 902 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 114 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 438 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 333 | 0.040 |
Why?
|
| Denmark | 1 | 2019 | 28 | 0.040 |
Why?
|
| Dabigatran | 1 | 2019 | 29 | 0.040 |
Why?
|
| Veterans Health | 1 | 2021 | 175 | 0.040 |
Why?
|
| Antithrombins | 1 | 2019 | 51 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 195 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 195 | 0.040 |
Why?
|
| Blood Component Removal | 1 | 2019 | 35 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 131 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1828 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2019 | 332 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 940 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 482 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 493 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5412 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 761 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1839 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 162 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2140 | 0.020 |
Why?
|
| Models, Biological | 1 | 2017 | 1443 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 814 | 0.020 |
Why?
|
| Heart Failure | 1 | 2024 | 2390 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 1380 | 0.020 |
Why?
|